Targeting resistance mechanisms in advanced prostate cancer
"DNMT and TET1 reprogramming as a targetable mechanism of resistance in advanced prostate cancer"
This study is looking at how advanced prostate cancer can change into a tougher form called neuroendocrine prostate cancer, and it's trying to find new ways to treat it to help patients feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11094021 on NIH RePORTER |
What this research studies
This research investigates how advanced prostate cancer can transform from a hormone-sensitive form to a more aggressive, hormone-resistant type known as neuroendocrine prostate cancer (NEPC). The study focuses on understanding the molecular and epigenetic changes that occur during this transformation, which could lead to new treatment strategies. By using patient-derived organoids and genetically engineered mouse models, researchers aim to identify potential therapeutic targets that could improve outcomes for patients with NEPC. The goal is to develop effective treatments for this challenging and aggressive form of prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced prostate cancer, especially those who have developed neuroendocrine features or have shown resistance to androgen-targeting therapies.
Not a fit: Patients with early-stage prostate cancer or those who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively treat advanced prostate cancer, particularly in patients whose cancer has become resistant to standard hormone therapies.
How similar studies have performed: Previous research has shown promise in targeting epigenetic changes in cancer, suggesting that this approach could be effective, although the specific focus on NEPC is relatively novel.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Rickman, David S. — Weill Medical Coll of Cornell Univ
- Study coordinator: Rickman, David S.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.